Key Highlights
- Anlon Healthcare signs SPA to acquire 56.67% of Bizotic Lifescience.
- Acquisition cost totals ₹3.79 crore for 25.5 lakh shares.
- Bizotic Lifescience reported ₹303.82 crore turnover as of FY25.
- Deal expected to close within three months subject to conditions.
- Bizotic to become subsidiary after completion of acquisition.
Anlon Healthcare Limited has announced that it has entered into a Share Purchase Agreement (SPA) to acquire a 56.67% stake in Bizotic Lifescience Private Limited. The agreement involves the purchase of 25.5 lakh equity shares at ₹14.89 per share, amounting to a total cash consideration of ₹3,79,69,500.
Following the completion of the transaction, Anlon Healthcare will gain management control of Bizotic Lifescience, thereby making it a subsidiary. The acquisition aims to strengthen the company’s pharmaceutical manufacturing capabilities by providing immediate access to ready-to-operate facilities.
Bizotic Lifescience, incorporated in 2015, is engaged in the manufacturing and export of active pharmaceutical ingredients (APIs), industrial chemicals and intermediates, along with offering contract research and manufacturing services. It recorded a turnover of ₹3,038.20 lakh for the financial year 2024–25, with ₹1,893.89 lakh reported up to October 2025.
Anlon Healthcare noted that the transaction serves as a strategic brownfield investment, enabling faster operational readiness compared to a greenfield project. This is expected to reduce regulatory timelines, accelerate production rollout and support earlier revenue generation.
The acquisition is expected to be completed within three months, subject to customary closing conditions. The company also confirmed that no related-party involvement or regulatory approvals are required for the transaction.